$EYPT

Zaderej Karen L. purchased $52K of EYPT

Zaderej Karen L. purchased 10,600 shares of EyePoint, Inc. (EYPT) at $4.93 on 2026-08-18.

Original reporting
SEC EDGAR · Zaderej Karen L.
Published Aug 18, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EYPT
Bullish
medium confidence
Mentioned
$EYPT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EYPTBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 10,600 shares at $4.93 on 2026-08-18, with holdings after the trade of 49,100 shares.

02

Market read

Traders may treat the Form 4 as a small sentiment input, but it does not introduce new operating or financial information.

03

What to watch

The filing notes no 10b5-1 plan, but it still does not provide context on motivation, timing constraints, or whether the director has other concurrent transactions.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, same day as the reported purchase date

Background

The article is an SEC Form 4 insider transaction disclosure for EyePoint, Inc.

Company-level read

Ticker impact

$EYPTBullishMedium confidence
Context

EyePoint director Zaderej Karen L. bought 10,600 shares on 2026-08-18 at $4.93, totaling $52,258, per Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small versus market-moving events.

Evidence & confidence

The filing is a primary-source Form 4 and the buyer is a director, but the transaction size is relatively small and there is no accompanying company-specific news (no guidance, trial, contract, or regulatory action).

Market effects

No clear sector read-through; this is a single-company insider transaction without new clinical or regulatory information.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect near-term operational improvements.

Key entities

  • EyePoint, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Zaderej Karen L.

    Director who purchased 10,600 shares for $52,258 on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EYPTMedAI 8/10

EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Kirby McInerney LLP is investigating EyePoint Pharmaceuticals (NASDAQ: EYPT) for potential securities fraud. The probe follows the company's Phase 3 trial failure for DURAVYU, which caused its stock to drop 67% on August 17, 2026. CEO Jay S. Duker had previously expressed confidence in the trial results. The firm is seeking information from investors.

$EYPTHighAI 9/10

EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal

EyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have

$EYPTMed

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

EyePoint Inc. (EYPT) shares fell again in pre-market after a Phase 3 wet AMD trial setback. RBC Capital downgraded EYPT to Sector Perform from Outperform and cut its price target about 86% to $5, citing Duravyu’s failure to meet the primary endpoint versus aflibercept. RBC and H.C. Wainwright said regulatory and clinical uncertainty could persist; results expected in Q4.

$EYPTHighAI 8/10

EyePoint's DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint; Stock Plunges

EyePoint (EYPT) reported topline Phase 3 LUGANO results for DURAVYU (vorolanib intravitreal insert) in wet AMD. The trial missed the primary endpoint versus aflibercept in the full dataset, but an ad hoc analysis excluding a small cohort showed non-inferiority (p=0.0096). Secondary results included a 42% treatment-burden reduction (p<0.0001). LUCIA data expected Q4 2026.